Last updated August 23, 2026
Key finding
At 12 months HbA1c was significantly higher in the liraglutide arm (HbA1c:10.9 mmol/mol, 1.1, 20.6, p = 0.032)
This pilot randomized controlled trial evaluated the efficacy and safety of liraglutide in participants undergoing laparoscopic adjustable gastric banding, revealing significant weight gain and HbA1c increase at 12 months in the liraglutide group.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This pilot randomized controlled trial evaluated the efficacy and safety of liraglutide in participants undergoing laparoscopic adjustable gastric banding, revealing significant weight gain and HbA1c increase at 12 months in the liraglutide group.
These findings suggest that liraglutide may not be beneficial for weight management or glycemic control in patients undergoing gastric banding, raising questions about its use in this population. Clinicians should consider these outcomes when prescribing liraglutide for weight-related issues in similar patients.
Small sample size limits generalizability. Short follow-up duration may not capture long-term effects. No significant adverse events reported, but further monitoring needed.
Published in
Publication details and source links for this paper.
Claudia C, Laurence JD, James C, et al. Efficacy and safety of liraglutide in participants undergoing laparoscopic adjustable gastric banding: a pilot randomized controlled trial. International Journal of Obesity (2005). 2023;47(11):1132-1142. doi:10.1038/s41366-023-01368-4
At 6 months, no significant difference in HbA1c between liraglutide and placebo (0.2 mmol/mol, p = 0.98).
At 6 months, no significant difference in body weight between liraglutide and placebo (2.0 kg, p = 0.50).
At 12 months, HbA1c was significantly higher in the liraglutide group (10.9 mmol/mol, p = 0.032).
At 12 months, body weight was significantly higher in the liraglutide group (8.2 kg, p = 0.02).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Liraglutide and Adverse events incidence, Body weight, HbA1c.
This study contributes evidence to
Primary intervention
Liraglutide
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
3
Evidence pairs
903
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Liraglutide → Adverse events incidence
Liraglutide → Adverse events incidence
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
6 results
4 results
6 results
6 results
4 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.
GLP-1 Receptor Agonists may affect body weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Strong | EvidenceScore™ 82.9 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.
Current evidence does not show a clear reduction in adverse events incidence with Liraglutide.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Adverse events incidence
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
